AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Dublin, April 13, 2018 -- The "Acute Decompensated Heart Failure Forecast and Market Analysis to 2034" report has been added to ResearchAndMarkets.com's offering.
Acute decompensated heart failure (ADHF) is defined as the sudden worsening of heart failure symptoms (mainly edema, dyspnea, and fatigue), which results in severe respiratory distress. ADHF is categorized into hemodynamic stages based on the degree of perfusion and pulmonary capillary wedge pressure. Despite improvements in treatment, ADHF is a burdensome disease associated with high hospitalization and mortality rates in the elderly population.
Recent events and opinion
- ADHF treatment is focused on hemodynamic stabilization and alleviation of symptoms.
- The author estimates that in 2016, there were 1.2 million diagnosed incident cases of ADHF in the US, Japan, and five major EU markets.
- Natrecor and Simdax have had limited success in the highly genericized ADHF market.
- Discontinuations of ularitide and Reasanz have left the ADHF pipeline bare.
Key Topics Covered:
1 Treatment: Acute Decompensated Heart Failure (Published on 19 January 2018)
- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Current Treatment Options
- Prescribing Trends
2 Epidemiology: Acute Decompensated Heart Failure (Published on 18 January 2018)
- Executive Summary
- Disease Background
- Sources And Methodology
- Forecast
- Epidemiologist Insight
- Strengths And Limitations
- Bibliography
- Appendix: Additional Sources
3 Marketed Drugs: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)
- Executive Summary
- Product Overview
- Diuretics
- Vasodilators
- Inotropic Agents
- Other Drug Classes
- Product Profile: NATRECOR
- Product Profile: SIMDAX
4 Pipeline: Acute Decompensated Heart Failure (ADHF) (Published on 15 February 2018)
- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Product Profile (Late Stage): BMS-986231
For more information about this report visit https://www.researchandmarkets.com/research/gn65vq/world_acute?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology
